Search results
Showing 1 to 13 of 13 results for tenofovir
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B. This is because Gilead did not provide an evidence submission.
Show all sections
Sections for TA435
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC
safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of...
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
Discontinued Reference number: GID-TAG414
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
This advice has been updated and replaced by NICE guideline NG221.